The fact is no one really knows how high up is for this company with Belviq and its many applications, plus their pipeline of other products. Cash rich with little to no debt. They have money to fund additional trials, and don't need help in doing so from predatory pharma's or venture capital. Big Pharma usually waits until a bio company is strapped for funding, yet has a terrific product, before jumping in and buying them out. ARNA is not in that situation, which is going to make an offer price (eventually) by BP a big problem. How long can you let a company like this grow and prosper? Gilead Science paid $11B for Pharmasset who has a unique Hep-C product. So where on the scale does Hep-C compare in numbers to obesity and diabetes in potential revenues? Jack has to have people knocking at his door to get involved. Eisai and Ildong are already onboard - so who is next - Europe, China, and etc.? My point is, ARNA does not have to sell now or ever.